Earnings Feed
Start Free
Dyne Therapeutics, Inc.·4

Apr 17, 4:05 PM ET

Kersten Dirk 4

Research Summary

AI-generated summary

Updated

Dyne Therapeutics (DYN) Director Dirk Kersten Sells 99,613 Shares

What Happened
Dirk Kersten, a director of Dyne Therapeutics (DYN), disposed of a total of 99,613 shares in open-market sales on April 15–16, 2026, generating aggregate proceeds of about $2.03 million. The sales were executed pursuant to a Rule 10b5-1 trading plan adopted by ForDyne B.V. on November 11, 2025. Specific transactions reported: 81,840 shares (weighted avg $20.27) for $1,659,044; 11,116 shares (weighted avg $21.10) for $234,591; and 6,657 shares (weighted avg $20.06) for $133,523. These were sales (not purchases), which are often routine dispositions under prearranged plans.

Key Details

  • Transaction dates: April 15, 2026 (81,840 shares) and April 16, 2026 (11,116 and 6,657 shares).
  • Reported proceeds: approximately $2,027,158 total.
  • Prices: weighted-average prices reported; individual execution prices fell in ranges noted in the filing:
    • 81,840 shares: weighted avg $20.27 (executions within $20.00–$20.99).
    • 11,116 shares: weighted avg $21.10 (executions within $21.00–$21.345).
    • 6,657 shares: weighted avg $20.06 (executions within $20.00–$20.16).
  • Plan: Sales made pursuant to a Rule 10b5-1 trading plan adopted by ForDyne B.V. on Nov 11, 2025.
  • Ownership/agency: The shares were held directly by ForDyne B.V.; footnotes describe Forbion-related entities and partners (including Kersten) that may be deemed to have voting/dispositive power over portions of ForDyne’s holdings. The reporting person disclaims beneficial ownership except to the extent of his pecuniary interest.
  • Filing timeliness: Form 4 was filed April 17, 2026; filing appears timely under the two-business-day rule.

Context

  • These were sales executed via a pre-established 10b5-1 plan, which is a common mechanism for insiders to sell shares according to a preset schedule and is typically treated as routine rather than an ad hoc signal of company prospects.
  • The filing provides weighted-average prices and execution ranges; the reporting person has offered to supply full per-price breakdowns on request.
  • This was institutional/managed trading through ForDyne rather than a direct personal open-market sale by an individual beneficial owner; footnotes describe the chain of management and delegation among Forbion-related entities.